Omeros Future Growth

Future criteria checks 2/6

Omeros is forecast to grow earnings and revenue by 39.1% and 68.8% per annum respectively while EPS is expected to grow by 44.8% per annum.

Key information

39.1%

Earnings growth rate

44.8%

EPS growth rate

Pharmaceuticals earnings growth	21.3%
Revenue growth rate	68.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:3O8 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	26	-126	N/A	N/A	2
12/31/2025	8	-147	N/A	N/A	2
12/31/2024	N/A	-170	N/A	N/A	2
9/30/2024	N/A	-185	-155	-155	N/A
6/30/2024	N/A	-200	-156	-155	N/A
3/31/2024	N/A	-179	-142	-142	N/A
12/31/2023	N/A	-175	74	75	N/A
9/30/2023	N/A	-182	84	84	N/A
6/30/2023	N/A	-185	90	90	N/A
3/31/2023	N/A	-182	103	103	N/A
12/31/2022	N/A	-182	-87	-86	N/A
9/30/2022	N/A	-183	-79	-79	N/A
6/30/2022	N/A	-173	-77	-77	N/A
3/31/2022	N/A	-181	-85	-85	N/A
12/31/2021	N/A	-192	-110	-110	N/A
9/30/2021	-63	-217	-110	-110	N/A
6/30/2021	-37	-211	-121	-121	N/A
3/31/2021	-24	-194	-131	-131	N/A
12/31/2020	N/A	-173	-100	-100	N/A
9/30/2020	97	-130	-105	-105	N/A
6/30/2020	100	-108	-78	-77	N/A
3/31/2020	114	-89	-56	-56	N/A
12/31/2019	N/A	-147	-60	-60	N/A
9/30/2019	100	-79	-62	-62	N/A
6/30/2019	75	-102	-92	-91	N/A
3/31/2019	50	-121	-106	-105	N/A
12/31/2018	30	-127	-104	-104	N/A
9/30/2018	22	-120	-84	-83	N/A
6/30/2018	39	-88	N/A	-58	N/A
3/31/2018	54	-68	N/A	-35	N/A
12/31/2017	65	-53	N/A	-36	N/A
9/30/2017	64	-57	N/A	-43	N/A
6/30/2017	54	-63	N/A	-43	N/A
3/31/2017	46	-61	N/A	-48	N/A
12/31/2016	42	-67	N/A	-52	N/A
9/30/2016	35	-67	N/A	-57	N/A
6/30/2016	27	-73	N/A	-61	N/A
3/31/2016	21	-77	N/A	-64	N/A
12/31/2015	14	-75	N/A	-65	N/A
9/30/2015	7	-76	N/A	-64	N/A
6/30/2015	4	-74	N/A	-66	N/A
3/31/2015	1	-76	N/A	-64	N/A
12/31/2014	1	-74	N/A	-58	N/A
9/30/2014	1	-55	N/A	-43	N/A
6/30/2014	1	-50	N/A	-38	N/A
3/31/2014	1	-46	N/A	-32	N/A
12/31/2013	2	-40	N/A	-30	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3O8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 3O8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 3O8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 3O8's revenue (68.8% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 3O8's revenue (68.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 3O8's Return on Equity is forecast to be high in 3 years time

Omeros Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

New major risk - Financial position

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

No longer forecast to breakeven

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association

Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab

Omeros Corporation Announces Extension of U.S. Food and Drug Administration Review Period for Narsoplimab in HSCT-TMA

Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ Pivotal Trial of Narsoplimab for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.54 loss in 1Q 2020)

Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

Full year 2020 earnings released: US$2.42 loss per share (vs US$1.71 loss in FY 2019)

Revenue misses expectations

Omeros Corporation to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: €18.15

Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer

New 90-day high: €16.20

Omeros Corporation Announces Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA

New 90-day high: €12.40

Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm Separate Payment for Omeros’ FDA-Approve OMIDRIA in Ambulatory Surgery Centers

New 90-day high: €11.37

Omeros Corporation Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

Third quarter 2020 earnings released: US$0.66 loss per share

Revenue beats expectations

Omeros Corporation to Report Q3, 2020 Results on Nov 09, 2020

Omeros Corporation to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA

New 90-day low: €8.04

Omeros Corporation has completed a Follow-on Equity Offering in the amount of $100.05 million.

First half earnings released

New 90-day low - €11.27

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies